Marinus Pharmaceuticals, Inc.

MRNS

US56854Q2003

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 16:00:00 2024-07-05 EDT			5-day change	1st Jan Change
1.2 ^USD	-0.83%		+2.56%	-88.96%

07-01	Marinus Pharmaceuticals, Inc.(NasdaqGM:MRNS) dropped from Russell 3000E Growth Index	CI
07-01	Marinus Pharmaceuticals, Inc.(NasdaqGM:MRNS) dropped from Russell 2000 Growth Index	CI

Marinus Pharmaceuticals, Inc.(NasdaqGM:MRNS) dropped from Russell 2000 Index

July 30, 2024

Latest news about Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals, Inc.(NasdaqGM:MRNS) dropped from Russell 3000E Growth Index	06-30	CI
Marinus Pharmaceuticals, Inc.(NasdaqGM:MRNS) dropped from Russell 2000 Growth Index	06-30	CI
Marinus Pharmaceuticals, Inc.(NasdaqGM:MRNS) dropped from Russell 2500 Index	06-30	CI
Marinus Pharmaceuticals, Inc.(NasdaqGM:MRNS) dropped from Russell 3000 Index	06-30	CI
Marinus Pharmaceuticals, Inc.(NasdaqGM:MRNS) dropped from Russell 2000 Index	06-30	CI
Marinus Pharmaceuticals, Inc.(NasdaqGM:MRNS) dropped from Russell 3000 Growth Index	06-30	CI
Marinus Pharmaceuticals, Inc.(NasdaqGM:MRNS) dropped from Russell Small Cap Comp Growth Index	06-30	CI
Marinus Pharmaceuticals, Inc.(NasdaqGM:MRNS) dropped from Russell 2000 Dynamic Index	06-30	CI
Marinus Pharmaceuticals, Inc.(NasdaqGM:MRNS) dropped from Russell Small Cap Completeness Index	06-30	CI
Marinus Pharmaceuticals, Inc.(NasdaqGM:MRNS) dropped from Russell 3000E Index	06-30	CI
Marinus Pharmaceuticals, Inc.(NasdaqGM:MRNS) dropped from Russell 2500 Growth Index	06-30	CI
Marinus Pharmaceuticals, Inc.(NasdaqGM:MRNS) dropped from S&P Pharmaceuticals Select Industry Index	06-23	CI
Sector Update: Health Care Stocks Decline Premarket Monday	06-17	MT
Top Premarket Decliners	06-17	MT
Marinus Pharmaceuticals Epilepsy Treatment Falls Short in Phase 3 Study	06-17	MT
Marinus Pharmaceuticals Announces Topline Results from Phase 3 Rise Trial of IV Ganaxolone in Refractory Status Epilepticus	06-17	CI
Marinus Pharmaceuticals, Inc. Enter into an Amendment to Its Previously Disclosed Credit Agreement with Oaktree Fund Administration, Llc	06-06	CI
Sector Update: Health Care Stocks Mixed Late Afternoon	05-17	MT
Sector Update: Health Care	05-17	MT
Marinus Completes Enrollment in Tuberous Sclerosis Complex Trial; Gets New Patent	05-17	MT
Marinus Pharmaceuticals, Inc. Announces Key Business Updates for Tuberous Sclerosis Complex Program	05-17	CI
Earnings Flash (MRNS) MARINUS PHARMACEUTICALS Reports Q1 Revenue $7.7M, vs. Street Est of $9.1M	05-08	MT
Marinus Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-08	CI
Marinus Pharmaceuticals, Inc. Increases Earnings Guidance for Full Year 2024	05-08	CI
HC Wainwright Adjusts Price Target on Marinus Pharmaceuticals to $11 From $27, Maintains Buy Rating	05-07	MT

Chart Marinus Pharmaceuticals, Inc.

Duration

Period

More charts

Marinus Pharmaceuticals, Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the development of innovative therapeutics for the treatment of seizure disorders, including rare genetic epilepsies and status epilepticus, which includes the use of ZTALMY (ganaxolone). Its U.S. Food and Drug Administration (FDA) approved the Companyâs new drug application for the use of ZTALMY oral suspension CV for the treatment of seizures associated with Cyclin-dependent Kinase-like 5 (CDKL5) Deficiency Disorder (CDD) in patients two years of age and older. The Company is also developing ganaxolone for the treatment of other rare genetic epilepsies, including Tuberous Sclerosis Complex (TSC) and for the treatment of Refractory Status Epilepticus (RSE). It is developing ganaxolone in formulations for two different routes of administration: intravenous (IV) and oral to maximize therapeutic reach for adult and pediatric patients in acute and chronic care settings.

Sector

Pharmaceuticals

Calendar

2024-08-07 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Marinus Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.2 USD

Average target price

6.667 USD

Spread / Average Target

+455.56%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
MARINUS PHARMACEUTICALS, INC.	-88.96%	65.92M
ELI LILLY AND COMPANY	+56.89%	823B
NOVO NORDISK A/S	+39.52%	627B
JOHNSON & JOHNSON	-6.55%	353B
MERCK & CO., INC.	+15.99%	320B
ABBVIE INC.	+7.92%	295B
ASTRAZENECA PLC	+13.74%	239B
NOVARTIS AG	+13.83%	220B
ROCHE HOLDING AG	-0.49%	219B
AMGEN INC.	+7.94%	167B

Other Pharmaceuticals